RESUMO
BACKGROUND/AIMS: The role of induction chemotherapy (IC) for eyeball preservation has not been established in head and neck squamous cell carcinoma (HNSCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement frequently leads to eyeball exenteration with a margin of safety. We evaluated the treatment outcomes, including survival and eyeball preservation, of patients who received IC for HNSCC of the PNSNC. METHODS: We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC. We analyzed response, eyeball preservation rate, and overall survival. RESULTS: Tumors were located in the paranasal sinus (n = 14) or nasal cavity (n = 7). Most patients had stage T4a (n = 10) or T4b (n = 7) disease. More than half of the patients received a chemotherapy regimen of docetaxel, fluorouracil, and cisplatin (n = 11). Thirteen patients (61.9%) achieved a partial response after IC and 15 patients (71.4%) achieved T down-staging. Among 17 patients with stage T4 disease, which confers a high risk of orbital exenteration, 14 (82.4%) achieved preservation of the involved eye. The 3-year overall survival (OS) rate of patients who achieved a partial response to IC was 84.6%. The 3-year OS rate of patients with stable disease or disease progression after IC was 25.0% (p = 0.038). CONCLUSIONS: IC could be considered for down-staging patients with advanced T-stage disease. It could also be a reasonable option for eyeball preservation in locally advanced HNSCC of the PNSNC.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Olho , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Quimioterapia de Indução/métodos , Cavidade Nasal/efeitos dos fármacos , Neoplasias Nasais/tratamento farmacológico , Tratamentos com Preservação do Órgão/métodos , Neoplasias dos Seios Paranasais/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/patologia , Quimioterapia Adjuvante , Cisplatino/administração & dosagem , Progressão da Doença , Docetaxel , Feminino , Fluoruracila/administração & dosagem , Neoplasias de Cabeça e Pescoço/mortalidade , Neoplasias de Cabeça e Pescoço/patologia , Humanos , Quimioterapia de Indução/efeitos adversos , Estimativa de Kaplan-Meier , Masculino , Prontuários Médicos , Pessoa de Meia-Idade , Cavidade Nasal/patologia , Terapia Neoadjuvante , Invasividade Neoplásica , Estadiamento de Neoplasias , Neoplasias Nasais/mortalidade , Neoplasias Nasais/patologia , Tratamentos com Preservação do Órgão/efeitos adversos , Neoplasias dos Seios Paranasais/mortalidade , Neoplasias dos Seios Paranasais/patologia , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Carcinoma de Células Escamosas de Cabeça e Pescoço , Taxa de Sobrevida , Taxoides/administração & dosagem , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
Malnutrition affects 40-50% of patients with ear, nose and throat (ENT) cancer. The aim of this study was to assess changes induced by a specific nutritional supplement enriched with n-3 polyunsaturated fatty acids, fiber and greater amounts of proteins and electrolytes, as compared with a standard nutritional supplement, on markers of inflammation, oxidative stress and metabolic status of ENT cancer patients undergoing radiotherapy (RT). Fourteen days after starting RT, 26 patients were randomly allocated to one of two groups, 13 supplemented with Prosure, an oncologic formula enriched with n-3 polyunsaturated fatty acids, fiber and greater amounts of proteins and electrolytes (specific supplement), and 13 supplemented with Standard-Isosource (standard supplement). Patients were evaluated before RT, and 14, 28 and 90 days after starting RT. The results showed that there were no significant differences between the groups, but greater changes were observed in the standard supplement group, such as a decline in body mass index (BMI), reductions in hematocrit, erythrocyte, eosinophil and albumin levels, and a rise in creatinine and urea levels. We concluded that metabolic, inflammatory and oxidative stress parameters were altered during RT, and began to normalize at the end of the study. Patients supplemented with Prosure showed an earlier normalization of these parameters, with more favorable changes in oxidative stress markers and a more balanced evolution, although the difference was not significant.
Assuntos
Suplementos Nutricionais , Neoplasias da Orelha/complicações , Ácidos Graxos Insaturados/uso terapêutico , Desnutrição/tratamento farmacológico , Neoplasias Nasais/complicações , Estresse Oxidativo/efeitos dos fármacos , Neoplasias Faríngeas/complicações , Antioxidantes/metabolismo , Biomarcadores/metabolismo , Índice de Massa Corporal , Proteína C-Reativa/análise , Fibras na Dieta/uso terapêutico , Neoplasias da Orelha/tratamento farmacológico , Neoplasias da Orelha/radioterapia , Eletrólitos/uso terapêutico , Feminino , Glutationa Peroxidase/metabolismo , Humanos , Peróxido de Hidrogênio/metabolismo , Inflamação/tratamento farmacológico , Interleucina-6/sangue , Masculino , Desnutrição/etiologia , Pessoa de Meia-Idade , Neoplasias Nasais/tratamento farmacológico , Neoplasias Nasais/radioterapia , Neoplasias Faríngeas/tratamento farmacológico , Neoplasias Faríngeas/radioterapiaAssuntos
Carcinoma Basocelular/tratamento farmacológico , Neoplasias do Colo/tratamento farmacológico , Neoplasias da Orelha/tratamento farmacológico , Orelha Externa , Melanoma/tratamento farmacológico , Neoplasias Primárias Múltiplas/tratamento farmacológico , Neoplasias Nasais/tratamento farmacológico , Fitoterapia/efeitos adversos , Extratos Vegetais/efeitos adversos , Sanguinaria , Automedicação/efeitos adversos , Neoplasias Cutâneas/tratamento farmacológico , Carcinoma Basocelular/diagnóstico , Neoplasias do Colo/diagnóstico , Neoplasias da Orelha/diagnóstico , Evolução Fatal , Humanos , Masculino , Melanoma/diagnóstico , Pessoa de Meia-Idade , Neoplasias Primárias Múltiplas/diagnóstico , Neoplasias Nasais/diagnóstico , Pomadas , Extratos Vegetais/administração & dosagem , Neoplasias Cutâneas/diagnósticoAssuntos
Carcinoma Basocelular/tratamento farmacológico , Cáusticos/efeitos adversos , Fármacos Dermatológicos/efeitos adversos , Neoplasias Faciais/tratamento farmacológico , Neoplasias Nasais/tratamento farmacológico , Fitoterapia/efeitos adversos , Preparações de Plantas/efeitos adversos , Automedicação/efeitos adversos , Adenocarcinoma/tratamento farmacológico , Alpinia , Carcinoma Basocelular/cirurgia , Cáusticos/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Neoplasias Faciais/cirurgia , Evolução Fatal , Humanos , Masculino , Pessoa de Meia-Idade , Cirurgia de Mohs , Pomadas/efeitos adversos , Preparações de Plantas/uso terapêutico , Rumex , Sanguinaria , Recusa do Paciente ao Tratamento , TrifoliumRESUMO
The study dealt with effect of chemoradiotherapy on the oxidant/antioxidant system in 57 patients with locally-advanced tumors (stage III-IV) of the maxilla, nasal and paranasal sinuses. Therapy modalities ranged from systemic chemoradiotherapy (22), intraarterial chemoradiotherapy + UHF-hyperthermia (20) and intraarterial chemotherapy + radiotherapy (15). The most frequent regimen of chemotherapy involved cisplatin 15 mg/ m2, total dose of 100 mg; fluorouracil 600 mg/m2, total dose of 2,000-3,000 mg, and doxorubicin 15 mg/m2, total dose of 40-60 mg. As far as telegammatherapy is concerned, all patients received STD of 3 Gy and TTD of 40-60 Gy. Unlike systemic chemoradiotherapy, continuous intraarterial chemoradiotherapy with UHF-hyperthermia or without it was followed by lower incidence of enhanced oxidative reaction response and tumor-related endotoxicosis.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Antioxidantes/metabolismo , Neoplasias Maxilares/sangue , Neoplasias Nasais/sangue , Neoplasias dos Seios Paranasais/sangue , Adolescente , Adulto , Idoso , Quimioterapia Adjuvante , Cisplatino/administração & dosagem , Doxorrubicina/administração & dosagem , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Humanos , Hipertermia Induzida , Infusões Intra-Arteriais , Masculino , Neoplasias Maxilares/tratamento farmacológico , Neoplasias Maxilares/patologia , Neoplasias Maxilares/radioterapia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias Nasais/tratamento farmacológico , Neoplasias Nasais/patologia , Neoplasias Nasais/radioterapia , Estresse Oxidativo , Neoplasias dos Seios Paranasais/tratamento farmacológico , Neoplasias dos Seios Paranasais/patologia , Neoplasias dos Seios Paranasais/radioterapia , Dosagem Radioterapêutica , Radioterapia Adjuvante , Adulto JovemRESUMO
We describe two paradigmatic cases where metronomic antitumor chemotherapy was successfully employed in patients not suitable for standard treatments. The first patient was affected by advanced soft tissue sarcoma but she also had ischemic cardiopathy. She received oral cyclophosphamide 50 mg once daily and methotrexate 2.5 mg bid twice weekly, obtaining a significant clinical response with a progression-free survival of 7 months. The second patient was over 70 years of age and suffered from metastatic gastric cancer. Because of his poor performance status he was given capecitabine 1500 mg daily, achieving a complete remission with a current disease-free survival of 13 months. In both cases no significant toxicities were observed.
Assuntos
Antineoplásicos/administração & dosagem , Fibrossarcoma/tratamento farmacológico , Neoplasias Nasais/tratamento farmacológico , Neoplasias Gástricas/tratamento farmacológico , Idoso , Antimetabólitos Antineoplásicos/administração & dosagem , Antineoplásicos Alquilantes/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Capecitabina , Quimioterapia Adjuvante , Ciclofosfamida/administração & dosagem , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Esquema de Medicação , Feminino , Fibrossarcoma/radioterapia , Fibrossarcoma/cirurgia , Fluoruracila/administração & dosagem , Fluoruracila/análogos & derivados , Humanos , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Neoplasias Nasais/radioterapia , Neoplasias Nasais/cirurgia , Neoplasias Gástricas/patologia , Resultado do TratamentoAssuntos
Carcinoma Basocelular/tratamento farmacológico , Neoplasias Nasais/tratamento farmacológico , Fitoterapia , Sanguinaria , Neoplasias Cutâneas/tratamento farmacológico , Humanos , Internet , Masculino , Pessoa de Meia-Idade , Cirurgia de Mohs , Preparações de Plantas/uso terapêutico , Automedicação/efeitos adversosRESUMO
INTRODUCTION: Nasal natural killer (NK) cell lymphoma that showed distant metastases generally showed an poor prognosis. We described a group of patients with these atypical presentation and that were treated with an intensive, short chemotherapy/radiotherapy regimen. METHODS: Sixty-one patients fulfilled the criteria for NK cell lymphoma with distant metastases and all have very poor prognostic factors: high clinical risk, multiple extranodal presentation and bulky disease (tumor mass >10 cm). They were treated with CMED (cyclophosphamide 2000 mg/m(2), iv, day 1, methotrexate 400 mg/m(2), iv, day 1(with leucovorin rescue), etoposide 400 mg/m(2) twice and dexametasone 40 mg daily for 4 days). If complete response (CR) was observed, they were received adjuvant radiotherapy (50 Gy) to nasal region. Patients with failure were treated with different salvage treatments. RESULTS: Forty nine patients achieved CR and 12 were considered failure, all patients that were failure and nine that relapse die secondary to tumor progression. Median follow-up were 46 months (range 34-68 months). Median has not been observed in relapse-free survival (RFS) and overall survival (OS). Actuarial curves at 5 years showed that RFS was 81% and OS was 65%. Treatment was well tolerated. CONCLUSIONS: Nasal NK cell lymphoma with distant metastases is considered an rare clinical entity, probably is under diagnosis because it has been included as stage III and IV in previous reports, that showed an very poor RFS and OS. The treatment herein report could achieve good response and outcome, but it is evident that more specific and aggressive therapy is necessary in these setting of patients.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Células Matadoras Naturais , Linfoma não Hodgkin/tratamento farmacológico , Metástase Neoplásica , Neoplasias Nasais/tratamento farmacológico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidade , Ciclofosfamida/administração & dosagem , Dexametasona/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Humanos , Leucovorina/administração & dosagem , Linfoma não Hodgkin/mortalidade , Linfoma não Hodgkin/patologia , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Radioterapia Adjuvante , Terapia de Salvação , Análise de Sobrevida , Resultado do TratamentoAssuntos
Carcinoma Basocelular/tratamento farmacológico , Neoplasias Nasais/tratamento farmacológico , Fitoterapia , Plantas Medicinais , Neoplasias Cutâneas/tratamento farmacológico , Carcinoma Basocelular/cirurgia , Bochecha/patologia , Terapias Complementares , Humanos , Masculino , Pessoa de Meia-Idade , Cirurgia de Mohs , Neoplasias Nasais/cirurgia , Pomadas , Rumex , Sanguinaria , Couro Cabeludo , Neoplasias Cutâneas/cirurgia , Falha de Tratamento , TrifoliumRESUMO
Patients may seek "alternative" or "non-traditional" therapies for dermatologic problems, frequently in search of a miraculous cure. However, many of these medicaments contain unknown compounds with questionable benefit and a potential for significant harm. We describe a patient who developed a large ulceration on her nose after applying "black and yellow salves" obtained from Mexico in an attempt to self-treat a basal cell carcinoma.
Assuntos
Carcinoma Basocelular/tratamento farmacológico , Terapias Complementares , Neoplasias Nasais/tratamento farmacológico , Pomadas , Neoplasias Cutâneas/tratamento farmacológico , Úlcera Cutânea/induzido quimicamente , Idoso , Feminino , Humanos , Automedicação/efeitos adversosRESUMO
UNLABELLED: THE AIM of this study was to estimate the value of HMRS in the diagnosis of brain lesions observed in children treated with chemo and radiotherapy and to assess the possibility to differentiate these lesions from neoplasm or recurrent disease. MATERIALS AND METHOD: We examined 6 children, aged from 7 to 15 yrs, 3 with brain tumours, 1 with esthesioneuroblastoma treated with chemo and radiotherapy and 2 patients with chemotherapy only, for other neoplasms (leukemia, Wilms tumor). Indications to perform imaging studies were routine for brain tumour patients (no clinical symptoms) and suspicion of disease recurrence in others. MR with 1.5 T scanner and additionally single voxel HMRS in PRESS sequence were performed. RESULTS: In all cases MRI showed extensive hyperintensive changes in brain tissue with significant mass effect. In 3 cases HMRS was within normal limits, in other 3 cases moderately elevated peak of choline and peak of lactate and lipids were found. In follow up examinations all lesions regressed and all patients are in good clinical condition. COMMENTS: It could be difficult to differentiate white matter injury from malignancies on MRI. HMRS in case of doubtful findings on MRI in children treated with chemo and radiotherapy, especially in those without symptoms of their disease, is a helpful method.
Assuntos
Encéfalo/patologia , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Lesões por Radiação/diagnóstico , Adolescente , Adulto , Encéfalo/efeitos dos fármacos , Encéfalo/efeitos da radiação , Quimioterapia Adjuvante/efeitos adversos , Criança , Terapia Combinada , Diagnóstico Diferencial , Estesioneuroblastoma Olfatório/tratamento farmacológico , Estesioneuroblastoma Olfatório/radioterapia , Feminino , Seguimentos , Humanos , Leucemia/tratamento farmacológico , Leucemia/radioterapia , Masculino , Recidiva Local de Neoplasia/diagnóstico , Neoplasias Nasais/tratamento farmacológico , Neoplasias Nasais/radioterapia , Polônia , Prótons , Lesões por Radiação/etiologia , Radioterapia Adjuvante/efeitos adversos , Sensibilidade e Especificidade , Fatores de Tempo , Tumor de Wilms/tratamento farmacológico , Tumor de Wilms/radioterapiaRESUMO
Thirty-two patients with nasal NK/T-cell lymphoma and disseminated disease (lung, skin, and bone marrow) were treated with an intensive combined therapy that consisted of three cycles of CMED (cyclophosphamide 2 g/m(2), metothrexate 200 mg/m(2), etoposide 600 mg/m(2), and dexamethasone 80 mg/m(2) with leucovorin rescue administered 24 h after) every 14 d, following high-dose radiotherapy: 55 Gy in 20 sesions to centrofacial region and three cycles more of the same chemotherapy regimen. To ameliorate the presence of severe granulocytopenia, granulocyte colony-stimulating factor, 5 microg/kg, daily for 14 d, begun on d 2 after chemotherapy, was administered. Complete response was achieved in 21 cases (65%); failure or progression was observed in 11 cases (35%). With a median follow-up of 69.1 mo, relapse has not been observed; thus, actuarial curves at 5 yr showed that event-free survival (EFS) is 100% in 21 patients and overall survival (OS) is 65%. Granulocytopenia grade IV was observed in 15% cycles, Nonhematological toxicity was mild and well tolerated. Radiotherapy was well tolerated; only mild mucositis was observed. Nasal NK/T-cell lymphoma is an rare presentation of malignant lymphoma (<1% of all cases) with a worse prognosis; less than 5% patients are alive free of disease at 1 yr. The use of intensive more specific chemotherapy and high dose of local radiotherapy, appear to be an excellent therapeutic approach with improvement in EFS and OS.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma de Células T/tratamento farmacológico , Linfoma de Células T/radioterapia , Neoplasias Nasais/tratamento farmacológico , Neoplasias Nasais/radioterapia , Adulto , Idoso , Agranulocitose/induzido quimicamente , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias da Medula Óssea/tratamento farmacológico , Neoplasias da Medula Óssea/radioterapia , Ciclofosfamida/administração & dosagem , Dexametasona/administração & dosagem , Intervalo Livre de Doença , Etoposídeo/administração & dosagem , Feminino , Seguimentos , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Humanos , Células Matadoras Naturais/efeitos dos fármacos , Células Matadoras Naturais/efeitos da radiação , Leucovorina/administração & dosagem , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/radioterapia , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Radioterapia Adjuvante , Indução de Remissão , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/radioterapia , Resultado do TratamentoRESUMO
We report here a 20-year-old man presenting with primary nasal NK/T-cell lymphoma which showed an aggressive clinical course spreading to the spleen and skin despite various treatments. Eight months after high dose chemotherapy followed by autologous peripheral blood stem cell transplantation, acute appendicitis with perforation occurred and the patient underwent appendectomy. The histopathological diagnosis was NK/T-cell lymphoma of the appendix. Lymphoma of the appendix is extremely rare and the majority of appendiceal lymphomas are of B-cell origin. This is the first report of involvement of appendix by nasal NK/T-cell lymphoma.
Assuntos
Neoplasias do Apêndice/secundário , Linfoma de Células T/patologia , Neoplasias Nasais/patologia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Apendicectomia , Neoplasias do Apêndice/complicações , Neoplasias do Apêndice/cirurgia , Apendicite/etiologia , Bleomicina/administração & dosagem , Cisplatino/administração & dosagem , Terapia Combinada , Ciclofosfamida/administração & dosagem , Citarabina/administração & dosagem , Doxorrubicina/administração & dosagem , Infecções por Vírus Epstein-Barr , Etoposídeo/administração & dosagem , Humanos , Perfuração Intestinal/etiologia , Células Matadoras Naturais/patologia , Leucovorina/administração & dosagem , Linfoma de Células T/complicações , Linfoma de Células T/tratamento farmacológico , Linfoma de Células T/radioterapia , Masculino , Metotrexato/administração & dosagem , Metilprednisolona/administração & dosagem , Compostos de Nitrosoureia/administração & dosagem , Neoplasias Nasais/tratamento farmacológico , Prednisona/administração & dosagem , Neoplasias Cutâneas/secundário , Neoplasias Esplênicas/secundário , Infecções Tumorais por Vírus , Vincristina/administração & dosagemRESUMO
OBJECTIVE: To develop a slow-release carboplatin formulation for intratumoral administration to cats. DESIGN: Preliminary study to analyze pharmacokinetic effects of purified sesame oil in the carboplatin formulation for intratumoral administration, and a second study to evaluate the efficacy and toxicosis of intratumoral administration of carboplatin in purified sesame oil. ANIMALS: 23 cats with squamous cell carcinomas of the nasal plane. PROCEDURE: Eight cats with advanced-stage tumors were submitted to intratumoral administration of 100 mg of carboplatin/m2 of body surface area, with or without purified sesame oil, using a two-period, cross-over design. Fifteen additional cats were treated by intratumoral administration of carboplatin in purified sesame oil. Four weekly intratumoral chemotherapy injections of carboplatin in purified sesame oil at a dosage of 1.5 mg/cm3 of tissue were given. RESULTS: Purified sesame oil in the formulation significantly reduced systemic exposure to carboplatin and drug leakage from the sites of injection. Cumulative effects of repeated intratumoral administrations on plasma concentrations of carboplatin were not observed. Systemic toxicosis was not observed, and local toxicosis was minimal. Healing of ulcerated lesions was not compromised. Rates of complete clinical tumor clearance and complete response were 67 and 73.3%, respectively. Product-limit estimates of mean progression-free survival times was 16 +/- 3.3 months. The 1-year progression-free survival rate was 55.1 +/- 13%. Local recurrence was observed in 7 cats; 4 had marginal tumor recurrence, and 3 had in-field and marginal tumor recurrence. CONCLUSIONS: Intratumoral carboplatin chemotherapy is safe and effective for cats with squamous cell carcinoma of the nasal plane. Future studies to improve treatment efficacy could include evaluation of increased dose-intensity as well as combination of this modality with radiotherapy. CLINICAL RELEVANCE: Intratumoral administration of carboplatin in a water-sesame-oil emulsion was found to be a practical and effective new treatment for facial squamous cell carcinomas in cats.
Assuntos
Antineoplásicos/uso terapêutico , Carboplatina/uso terapêutico , Carcinoma de Células Escamosas/veterinária , Doenças do Gato/tratamento farmacológico , Neoplasias Nasais/veterinária , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacocinética , Carboplatina/administração & dosagem , Carboplatina/farmacocinética , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/mortalidade , Doenças do Gato/mortalidade , Doenças do Gato/radioterapia , Gatos , Terapia Combinada , Estudos Cross-Over , Preparações de Ação Retardada , Relação Dose-Resposta a Droga , Recidiva Local de Neoplasia , Neoplasias Nasais/tratamento farmacológico , Neoplasias Nasais/mortalidade , Óleo de Gergelim/farmacologia , Taxa de SobrevidaRESUMO
We have described a 20-year-old man with recurrent intranasal papillomas that were successfully treated by twice-weekly applications of 25% podophyllin in tincture of benzoin.
Assuntos
Neoplasias Nasais/tratamento farmacológico , Papiloma/tratamento farmacológico , Podofilina/uso terapêutico , Adulto , Humanos , Masculino , Recidiva Local de NeoplasiaRESUMO
From 1954 through 1971, 47 patients with malignant tumors of the nasal cavity and paranasal sinuses were treated with an entire eye included in the tumor dose volume. All patients were treated with megavoltage radiation and received approximately 6,000 rads in 30 fractions in six weeks. Two thirds of the patients treated by irradiation alone had no problems with vision or difficulties related to treatment of the eye. When 5-fluorouracil (5-FU) was used in conjunction with high-dose radiotherapy, loss of vision was much more frequent and all patients had either visual loss or major clinical difficulties.